Evidence mapPaperPMID 22980301Full record

Trial reportAmerican heart journal2012

Troponin I release after intravenous treatment with high furosemide doses plus hypertonic saline solution in decompensated heart failure trial (Tra-HSS-Fur).

Gaspare Parrinello, Pietro Di Pasquale, Daniele Torres, Mauro Cardillo, Caterina Schimmenti, Umberto Lupo, Rossella Iatrino, Rossella Petrantoni, Carla Montaina, Salvatore Giambanco and 1 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in American heart journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06442280 (Enhanced Diuresis and Natriuresis in Acute Decompensated Heart Failure Patients Treated With SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution), which is not on this map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06442280 phase4unknown statusstarted 2024, after this paper: background citation

Enhanced Diuresis and Natriuresis in Acute Decompensated Heart Failure Patients Treated With SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution: A Clinical Trial

Ran2024Enrolled544Registered outcomes4Posted comparisons0ConditionsDiabetes Type 2, Heart Failure Acute, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection FractionArmsDapagliflozin Tablet, Furosemide Injection, Hypertonic Saline Solution, 1 Ml
Open the trial in the graph
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Diuretic Use in Heart Failure.Reviews in cardiovascular medicine · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Retroelements and formation of chimeric retrogenes.Cellular and molecular life sciences : CMLS · 2004
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Gaspare ParrinelloDepartment of Internal and Specialty Medicine, Chair of Clinical Pathophysiology, University of Palermo, Italy. gaspare.parrinello@unipa.it
Pietro Di Pasquale
Daniele Torres
Mauro Cardillo
Caterina Schimmenti
Umberto Lupo
Rossella Iatrino
Rossella Petrantoni
Carla Montaina
Salvatore Giambanco
Salvatore Paterna
University of Palermo · ITOspedale G.F. Ingrassia · ITBrigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh values of cardiac troponin in acute decompensated congestive heart failure (ADHF) identify patients at higher risk and worsened prognosis. A cardiac troponin increase during therapy indicates the need for more appropriate intervention, aimed at compensating cardiac disease and effectively minimizing myocardial wall stress and subsequent cytolysis. This study evaluated the effects of an intravenous high dose of furosemide with (group A) or without small volume hypertonic saline solution (HSS) (group B) on myocardial cytolysis in patients with ADHF.

methodsA total of 248 consecutive patients with ADHF (148 men, mean age 74.9 ± 10.9 years) were randomly assigned to group A or B. Plasma levels of cardiac troponin-I, brain natriuretic peptide, glomerular filtration rate by Modification of Diet in Renal Disease formula, bioelectrical impedance analysis measurements, and delta pressure/delta time (dP/dt) rate were observed on admission and discharge for all patients.

resultsWe observed a significant reduction of cardiac troponin in both groups and a significant improvement in renal function, hydration state, pulmonary capillary wedge pressure (P < .0001), end diastolic volume (P < .01), ejection fraction (P < .01), and dP/dt (P < .004) in group A. We also observed a significant reduction in body weight (64.4 vs 75.8 kg) (P < .001), cardiac troponin I (0.02 vs 0.31 ng/mL) (P < .0001) and brain natriuretic peptide (542 vs 1,284 pg/mL) (P < .0001), and hospitalization time (6.25 vs 10.2 days) (P < .0001) in the HSS group.

conclusionsThese data demonstrate that intravenous high doses of furosemide do not increase myocardial injury and, in addition, when associated to HSS, significantly reduce cardiac troponin I release. This behavior is mirrored by the achievement of improved hemodynamic compensation at echocardiography and body hydration normalization.

Indexed as

Administration, IntravenousAgedAged, 80 and overDiureticsDouble-Blind MethodDrug Therapy, CombinationEchocardiography, Doppler, ColorElectric ImpedanceFemaleFurosemideHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPotassiumDiureticsFurosemideNatriuretic Peptide, BrainPotassiumSaline Solution, HypertonicTroponin I

Identifiers

PMID22980301
OpenAlexW2065914213

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.